Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Обмен на изследователи2016–2019

EPIC · Exploiting Protein Complexes that Induce Cell-death

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2016-01-01 → 2019-12-31
Финансиране от ЕС
607 500 €
Участници
6
Схема
MSCA-RISE

Линиите свързват координатора с партньорите.

Накратко на български

Протеиновите комплекси, като например апоптозомата, регулират различните начини, по които клетките умират. Разбирането на тези процеси помага за откриването на нови лекарства и по-доброто тестване на токсичността на веществата.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Exploiting Protein Complexes that Induce Cell-death

Programmed cell death (PCD) occurs in many pathological situations from inflammation to ischaemia. PCD is also the mechanism through which many anti-cancer therapies act. After 20 years of PCD research it is now clear that there are several distinct PCD pathways, including apoptosis, necroptosis and pyroptosis. Many PCD processes appear to be regulated by the formation of large protein complexes that initiate cell the molecular events that eventually kill the cells. For example, the formation of a complex called the apoptosome induces apoptosis, formation of the necrosome induces necroptosis and formation of the inflammasome causes pyroptosis. As these protein complexes determine cell fate, blocking complex formation in diseases where cell death is unwanted or inducing complex formation in diseases where cell death is desirable could be a valuable therapeutic approach. Realizing this aim is currently limited by the absence of assays for complex formation that are suitable for screening purposes. Solving this problem requires a multi-disciplinary approach and the integration of research activities that are spread across different research groups. Completion of the project will provide new approaches to detect and investigate protein complexes that determine cell fate, providing new strategies for both drug-discovery and for in vitro toxicity testing.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The formation of specific protein complexes are key events in life-and-death decisions made by cells. Inappropriate decisions underpin a plethora of disease conditions from degenerative diseases to cancer while the role of the complexes in these processes make them important therapeutic targets. Our ability to develop small molecules to target death-inducing protein complexes has been hampered by an inability to measure complex formation in cells in real-time and by the absence of robust high-throughput assays for the discovery of new lead molecules that target these complexes. The proposed network (EPIC) will address both of these problems by developing new approaches to measure necrosome and apoptosome formation in real-time as well as new high-throughput and high-content screening assays using Fluorescence resonance transfer and split-luciferase technologies.EPIC will conform with the H2020 work programme by integrating research activity, novel reagents and expertise across Europe and world through the mobility, knowledge transfer and training of experienced and early stage researchers from within and without the EU. EPIC will realise the potential of researchers through the development of new skill-sets, the transfer new skills between academia and industry, and the development of career opportunities for EU ESRs and ERs. A key part of this activity is the mobility of non-EU researchers and the inward transfer of essential knowledge from outside the EU to benefit EU-based research. Establishment of EPIC through RISE will generate lead molecules with demonstrable utility and knowledge that will underpin applications to national funding agencies to sustain the communal effort beyond the life of the RISE award. It will also generate intellectual property that will enable the network to approach biotech and pharma to form academia-industry partnerships that will further develop small molecule leads as therapeutics.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз